Chapter 11
Statins in Atherosclerosis: Role of Immune Regulation
Claire Arnaud,
François Mach,
Claire Arnaud
Search for more papers by this authorFrançois Mach
Search for more papers by this authorClaire Arnaud,
François Mach,
Claire Arnaud
Search for more papers by this authorFrançois Mach
Search for more papers by this authorBook Editor(s):Ronald Ross Watson,
Douglas F. Larson,
Ronald Ross Watson
Department of Nutritional Sciences, The University of Arizona; and Sarver Heart Center, College of Medicine, The University of Arizona
Division of Health Promotion Sciences, Mel and Enid Zuckerman Arizona College of Public Health, The University of Arizona Tucson, AZ USA
Search for more papers by this authorDouglas F. Larson
Sarver Heart Center College of Medicine The University of Arizona Tucson, AZ USA
Search for more papers by this authorFirst published: 30 August 2007
Summary
This chapter contains section titled:
-
Introduction
-
Clinical evidence of statins pleiotropic effects
-
MHC-II expression
-
Leukocyte adhesion and migration
-
T-cell immune response
-
CD40—CD40L
-
Conclusion
-
References
References
- Lusis A.J. Atherosclerosis. Nature 2000; 407 (6801): 233–41.
- Hansson GK Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6 (7): 508–19.
- Maron DJ Fazio S Linton M.F. Current perspectives on statins. Circulation 2000; 101 (2): 207–13.
- Vaughan CJ Gotto AM Jr, Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35 (1): 1–10.
- Pedersen TR Kjekshus J Berg K et al. Randomised trial of cholesterol lowering in 4444 patients with coro-nary Heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9.
- Shepherd J. Fibrates and statins in the treatment of hyper-lipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16 (1): 5–13.
- Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21 (1): 3–5.
- Downs JR Clearfield M Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615–22.
- The Long-Term Intervention with Pravastatin in Is-chaemic Disease (LIPID) Study Group. Preventionofcar-diovascular events and death with pravastatin in patients with coronary Heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339 (19): 1349–57.
- Arnaud C Braunersreuther V Mach F. Toward im-munomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med 2005; 15 (6): 202–6.
- Van Aelst L D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997; 11 (18): 2295–322.
- Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279 (5350): 509–14.
- Ridker PM Cannon CP Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352 (1): 20–8.
- Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346 (8991–8992): 1647–53.
- Vaughan CJ Delanty N Basson C.T. Statin therapy and stroke prevention. Curr Opin Cardiol 2001; 16 (4): 219–24.
- Schwartz GG Olsson AG Ezekowitz M. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285 (13): 1711–8.
- Amarenco P Labreuche J Lavallee P Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35 (12): 2902–9.
- Vollmer T Key L Durkalski V et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363 (9421): 1607–8.
- McCarey DW McInnes PI Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004; 363 (9426): 2015–21.
- Poynter JN Gruber SB Higgins P. et al. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352 (21): 2184–92.
- Sever PS Dahlof B Poulter N. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361 (9364): 1149–58.
- Colhoun HM Betteridge DJ Durrington P. et al. Primary prevention of cardiovascular disease with atorvas-tatin in type 2 diabetes in the Collaborative Atorvas-tatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435): 685–96.
- Vaughan CJ Murphy MB Buckley B.M. Statins do more than just lower cholesterol. Lancet 1996; 348 (9034): 1079–82.
- Nissen SE Tuzcu EM Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352 (1): 29–38.
- Node K Fujita M Kitakaze M Hori M Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003; 108 (7): 839–43.
- Sherer Y Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 2002; 1 (1–2): 21–7.
- Steffens S Mach F. Anti-inflammatory properties of statins. Semin Vasc Med 2004; 4 (4): 417–22.
- Gurevich VS Shovman O Slutzky L Meroni PL Shoen-feld, Y. Statins and autoimmune diseases. Autoimmun Rev 2005; 4 (3): 123–9.
- Kobashigawa JA Katznelson S Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333 (10): 621–7.
- Wenke K Meiser B Thiery J et al. Simvastatin reduces graft vessel disease and mortality after Heart transplantation: a four-year randomized trial. Circulation 1997; 96 (5): 1398–402.
- Wenke K Meiser B Thiery J et al. Simvastatin initiated early after Heart transplantation: 8-year prospective experience. Circulation 2003; 107 (1): 93–7.
- Kwak B Mulhaupt F Myit S Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6 (12): 1399–402.
- Youssef S Stuve O Patarroyo J. et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420 (6911): 78–84.
- Kwak B Mulhaupt F Veillard N Pelli G Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gammainduced MHC class II expressioninhumanvascu-lar endothelial cells. Swiss Med Wkly 2001; 131 (3–4): 41–6.
- Sadeghi MM Tiglio A Sadigh K et al. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 2001; 71 (9): 1262–8.
- Greenwood J Steinman L Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to im-munomodulation. Nat Rev Immunol 2006; 6 (5): 358–70.
- Cybulsky MI Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251 (4995): 788–91.
- Prasad R Giri S Nath N Singh I Singh A.K. Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction. J Neurochem 2005; 94 (1): 204–14.
- Weitz-Schmidt G Welzenbach K Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7 (6): 687–92.
- Carlos TM Harlan J.M. Leukocyte-endothelial adhesion molecules. Blood 1994; 84 (7): 2068–101.
- Dustin ML Springer T.A. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989; 341 (6243): 619–24.
- Charo IF Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354 (6): 610–21.
- Gu L Okada Y Clinton S. et al. Absence of mono-cyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2 (2): 275–81.
- Boring L Gosling J Cleary M Charo I.F. Decreased lesion formation in CCR2–/–mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394 (6696): 894–7.
- Veillard NR Kwak, B, Pelli, G et al. Antagonismof RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004; 94 (2): 253–61.
- Mach F Sauty A Iarossi A. et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999; 104 (8): 1041–50.
- Haley KJ Lilly CM Yang J. et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 2000; 102 (18): 2185–9.
- Veillard NR Braunersreuther V Arnaud C et al. Sim-vastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006; 188 (1): 51–8.
- Gegg ME Harry R Hankey D et al. Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction. J Immunol 2005; 174 (4): 2327–35.
- Chung, HK, Lee, IK, Kang, H et al. Statininhibitsinterferon-gamma-induced expression of intercellular adhesion molecule-1(ICAM-1)invascularendothelialandsmooth muscle cells. Exp Mol Med 2002; 34 (6): 451–61.
- Rosenson RS Tangney CC Casey L.C. Inhibition of proin-flammatory cytokine production by pravastatin. Lancet 1999; 353 (9157): 983–4.
- Shimada K Miyauchi K Daida H. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation 2004; 109 (18): e213–4; author reply e213–4.
- Uyemura K Demer LL Castle S. et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97 (9): 2130–8.
- Mallat Z Besnard S Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85 (8): e17–24.
- Pinderski LJ Fischbein MP Subbanagounder G et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage pheno-types. Circ Res 2002; 90 (10): 1064–71.
- Schonbeck U Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58 (1): 4–43.
- Mach F Schonbeck U Sukhova GK Atkinson E Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394 (6689): 200–3.
- Lutgens E Gorelik L Daemen M. et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999; 5 (11): 1313–6.
- Foy TM Aruffo A Bajorath J Buhlmann JE Noelle R.J. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996; 14: 591–617.
- Schonbeck U Mach F Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 2000; 32 (7): 687–93.
- Mulhaupt F Matter CM Kwak B. et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59 (3): 755–66.
- Wagner AH Gebauer M Guldenzoph B Hecker M. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvas-tatin in human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22 (11): 1784–9.
- Schonbeck U Gerdes N Varo N et al. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells. Circulation 2002; 106 (23): 2888–93.
- Banchereau J Briere F Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767–811.
- Bobryshev YV Lord R.S. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatoryreactions. Cardiovasc Res 1998; 37 (3): 799–810.
- Yilmaz A Reiss C Tantawi O et al. HMG-CoA reduc-tase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004; 172 (1): 85–93.
